AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CANF

Can-Fite BioPharma Ltd.

Price · $CANFvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CANF in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CANF in the last 30 days.

Top stories · $CANFMore →
MAY 14·Investing.comHigh

D. Boral Capital upgrades Can-Fite BioPharma stock rating on oncology pipeline progress

D. Boral Capital upgraded Can-Fite BioPharma (CANF) to Buy from Hold, setting a price target of $7.00 due to progress in its oncology pipeline, specifically the advancement of Namodenoson into a Phase 2b pancreatic cancer study. The previous downgrade was attributed to a reverse stock split, not clinical deterioration. Can-Fite recently reported a net loss for 2025 but announced positive Phase 2a results for namodenoson in pancreatic cancer and received an Israeli patent for A3 adenosine receptor agonists for obesity.

MAR 4·Stock Titan

Biotech Can-Fite unlocks $4M to fund drug R&D and clinical trials

Can-Fite BioPharma Ltd. announced it has entered into a definitive agreement for the immediate exercise of warrants, expected to generate approximately $4.0 million in gross proceeds. These funds will be allocated towards research and development, clinical trials, and general corporate purposes. The company will also issue new unregistered warrants as part of the transaction.

MAR 4·Benzinga

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma's shares surged after its drug, Namodenoson, met the primary endpoint in a Phase 2a study for pancreatic cancer, demonstrating improved overall survival rates and a favorable safety profile. The company is also exploring the drug's efficacy in liver cancer and received a Canadian patent for its use as an anti-obesity therapy. Topline efficacy data for pancreatic cancer is expected in Q3 2026, and its stock is trading near its 52-week low.

News on $CANF

All news →